
Lipocine (LPCN) Stock Forecast & Price Target
Lipocine (LPCN) Analyst Ratings
Bulls say
Lipocine Inc. has a promising outlook due to the potential regulatory approval and commercialization of its oral testosterone replacement therapy, TLANDO, in Canada, which is expected to enhance the company's topline revenue significantly. Additionally, the promising results from LPCN 1154, an innovative formulation for postpartum depression with a rapid onset of action and impressive remission rates in clinical trials, position Lipocine advantageously within a niche market with notable unmet medical needs. Furthermore, management has identified limited promotional activities for existing testosterone replacement therapies in Canada, suggesting that TLANDO could capture substantial market share, bolstered by a recent exclusive licensing agreement for TLANDO in the U.S. with Verity.
Bears say
Lipocine Inc. reported a net loss of $3.2 million for the third quarter of 2025, highlighting the ongoing financial challenges faced by the company. The company is currently relying on the upcoming Phase 3 PPD trial for LPCN 1154, which poses significant risks, including potential failure in clinical trials, regulatory approval, and market competition. Additionally, concerns about dilution risk further compound the negative outlook for Lipocine, as these factors could adversely affect the company’s financial stability and future growth prospects.
This aggregate rating is based on analysts' research of Lipocine and is not a guaranteed prediction by Public.com or investment advice.
Lipocine (LPCN) Analyst Forecast & Price Prediction
Start investing in Lipocine (LPCN)
Order type
Buy in
Order amount
Est. shares
0 shares